Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 94 of the 96 references it cites were found in a registry or an index.

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

Open access
Merin, Noah, Kelly, Kevin · 2014 · Pharmaceuticals

Abstract

Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph8010001

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 1

  1. Kaufman, J.L., and Siegal, D. (2013, January 21). Haematologica. Clinical Profile of Once-Daily, Modified-Release Oprozomib Tablets in Patients with Hematologic Malignancies: Results of a Phase 1b/2 Trial. Proceedings of Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association, South San Francisco, CA, USA.

Cited by

See all 91

Metadata

Authors
Merin, N., & Kelly, K.
Affiliations
University of Southern California (US)
Corresponding author
Kelly, Kevin
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2014-12-24
Volume
8
Issue
1
Pages
1-20
ISSN
1424-8247 (ISSN-L)
OpenAlex
W1994895013
Cited by
90
References
96
Citations by year
2026: 2 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 6 · 2021: 12 · 2020: 5 · 2019: 7 · 2018: 12 · 2017: 6 · 2016: 13 · 2015: 5
FWCI
1.23
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
California Institute for Regenerative Medicine
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
multiple myeloma, proteasome inhibitors, bortezomib, carfilzomib, adverse drug reactions, combination therapy, plasma cell neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma. https://app.cochat.ai/papers/10.3390/ph8010001
The paper
Merin, N., & Kelly, K. (2014). Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma. Pharmaceuticals. https://doi.org/10.3390/ph8010001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.